Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH (Reuters) - Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented.